MA-IBASIS
2.3.2023 16:19:44 CET | Business Wire | Press release
iBASIS, the leading provider of communications solutions for operators and digital players worldwide, and Sequans Communications S.A. (NYSE: SQNS), a leading developer and provider of 5G/4G chips and modules, today announced that Actility, a leading provider of IoT connectivity platform, has chosen iBASIS and Sequans to roll out programmable cellular IoT solutions with eSIM and iSIM.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230227005808/en/
Actility had previously worked closely with iBASIS to enable roaming between private unlicensed networks powered by ThingPark EPC Connector and public networks, using Simfony’s CMP platform, now fully integrated with iBASIS’ Global Access for Things™ IoT portfolio. The longstanding partnership between iBASIS and Sequans has produced several successful proofs of concept.
The new ultra-low-power multi-technology trackers of Abeeway, a fully owned Actility subsidiary, will benefit from Sequans Monarch 2 LTE-M/NB-IoT platform with integrated iSIM and the connectivity profile provided by iBASIS, allowing the device to connect to cellular networks worldwide. Actility will also benefit from Sequans Monarch 2 being the first iSIM implementation that has achieved common criteria EAL5+ certification, allowing the use of iBASIS’ intelligent profile selection technology with remote update using multiple Tier-1 operator profiles as provided for eSIM.
iSIM is fully integrated in the cellular modem and microcontroller unit on a single system on chip (SoC). It relies on the existing eSIM infrastructure accessing 2/3/4/5G networks using the global footprint of iBASIS. iSIM is considered to be the future of connectivity technology for many IoT deployments.
An important step forward in the IoT industry, iSIM will positively influence device design in the areas of space optimization, and reduction of energy and power consumption. By eliminating the need for a separate SIM chip, iSIM will provide the customer with a more streamlined supply chain experience when manufacturing a device using cellular connectivity. The entire supply chain will benefit from the reduction of materials which will lead to lower costs for manufacturers.
According to Counterpoint Research, beyond 2027 iSIM is projected to take over as the dominant SIM form factor, with the shipments of iSIM-capable devices poised to scale to 7 billion units between 2021 and 2030.
With the iBASIS Global Access for Things™ industry-leading coverage, eSIM/iSIM enables enterprises to easily adopt a single global, remotely programmable SIM that provides mobile data connectivity to smart devices all over the world.
“After recent collaboration with iBASIS, adding iBASIS connectivity on our Monarch 2 module with eSIM, and having fully tested the global connectivity on iSIM, we are now advancing into an integrated production phase driven by a customer need,” said Louis Chuang, EVP of Sequans’ Massive IoT Business Unit. “We are thrilled to reach this important milestone with iBASIS whereby we can offer customers a powerful iSIM capability, along with low power consumption, cost-efficiency, and GNSS support.”
“After being recognized as a leader in the cellular IoT connectivity market with eSIMs, we are delighted to implement iSIM technology together with our trusted partner Sequans,” said Ajay Joseph, CEO IoT & CTO, iBASIS. “After many years of research and development, while deploying iSIM technology in trial environments, it is a great achievement by our teams. This once again underlines that iBASIS is a frontrunner and truly lives by its motto: ‘Be there first’. We strongly believe that iSIM will become a dominant factor within the IoT industry and I am proud to see that we are now able to provide our longstanding customer Actility with our proven IoT connectivity on iSIM.”
“Our focus is ultra-low-power industrial IoT connectivity. The new cellular trackers of our subsidiary Abeeway leverage LTE-M and NB-IoT, and our ThingPark EPC Connector for unlicensed private cellular networks (such as CBRS) rely on recent 3GPP slicing technologies,” said Olivier Hersent, CEO of Actility. “We needed cutting edge partners to support reliable LTE-M connections with PSM/eDRX options in permanent roaming as well as iSIMs: after extensive testing we selected Sequans for their ability to support iSIMs and because 100 percent of their software stack is developed in-house, and iBASIS for their ability to support complex integration and their focus on quality, based on proactive testing. Together, I think we form the dream team for industrial low-power IoT.”
To find out more, visit iBASIS in Hall 2, MR 2A6 and 2A8, and Sequans in Hall 5, Stand 5H40, at Mobile World Congress from February 27 to March 2 in Barcelona.
ABOUT iBASIS
iBASIS is the leading communications solutions provider enabling operators and digital players worldwide to perform and transform. Powered by Tofane Global, iBASIS is the first independent communications specialist, ranking third largest global wholesale voice operator, Top 3 LTE IPX vendor with 700+ LTE destinations, and a leading Carrier Cloud Communications player and IoT solution provider. iBASIS provides the end-to-end Global Access for Things™ connectivity solution, delivering single source cellular IoT access (LTE, LTE-M and NB-IoT) worldwide provisioned through GSMA-standard eSIM/eUICC technology. iBASIS today serves 1,000+ customers across 26 offices worldwide. For more information, please visit iBASIS.com.
ABOUT SEQUANS
Sequans Communications S.A. (NYSE: SQNS) is a leading developer and supplier of cellular IoT connectivity solutions, providing chips and modules for 5G/4G massive and broadband IoT. For 5G/4G massive IoT applications, Sequans provides a comprehensive product portfolio based on its flagship Monarch LTE-M/NB-IoT and Calliope Cat 1 chip platforms, featuring industry-leading low power consumption, a large set of integrated functionalities, and global deployment capability. For 5G/4G broadband IoT applications, Sequans offers a product portfolio based on its Cassiopeia Cat 4/Cat 6 4G and high-end Taurus 5G chip platforms, optimized for low-cost residential, enterprise, and industrial applications. Founded in 2003, Sequans is based in Paris, France with additional offices in the United States, United Kingdom, Israel, Hong Kong, Singapore, Finland, Taiwan, South Korea, and China. Visit Sequans online at www.sequans.com, and follow us on Twitter and LinkedIn.
ABOUT ACTILITY
Actility is the world leader in Low-Power Wide-Area Networks (LPWAN) industrial-grade connectivity solutions for the Internet of Things. Actility provides its ThingPark™ platform and network technology to deploy, operate and maintain public and private wireless IoT networks within a unified, scalable and versatile network infrastructure. The vast majority of nationwide LPWAN network service providers and hundreds of enterprises trust ThingPark™ all over the world. Through its subsidiary Abeeway, Actility also provides patented ultra-low power tracking solutions. ThingPark Market offers the largest selection of interoperable IoT gateways, devices and applications to simplify and accelerate deployment of numerous use cases. Contact us here: https://www.actility.com/contact
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230227005808/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release
Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom